Expansion and clinical validation of Markov model‐based quality‐adjusted life expectancy (QALE) simulations for head‐and‐neck cancer radiotherapy patients
Medical Physics · 2026
DOI: 10.1002/mp.70696 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Medical Physics, 2026. Verfasst von Sebastian Tattenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: INSA-Lyon, Universite Claude Bernard Lyon 1, CNRS, Inserm, CREATIS UMR 5220, U1294, Lyon, France. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Markov Chains, Quality-Adjusted Life Years, Life Expectancy. Die Arbeit nennt 35 Literaturangaben. Gefördert von: ANR HERESP, LabEx PRIMES, SIRIC LyriCAN+.
Abstract (Originalsprache)
Background
Radiotherapy treatment plan comparisons often utilize structure doses, tumor control probabilities (TCPs), and normal tissue complication probabilities (NTCPs), but such metrics do not reflect the duration for which a patient suffers from a developed toxicity. Markov models allowing for the simulation of the patient's entire lifetime post‐treatment and the determination of quality‐adjusted life expectancy (QALE) have been developed but generally disregard important considerations such as additional treatments received and second primary malignancies (SPMs). Clinical validation also largely remains outstanding.
Purpose
This study aims to expand and clinically validate a Markov model focusing on head‐and‐neck cancer patients.
Methods
A Markov model considering tumor control, healthy tissue toxicities, distant metastases, radiation‐associated secondary cancer, and death from various causes was expanded to further include additional treatments received, SPMs, and the patient's smoking history. For each of 148 head‐and‐neck cancer patients, 437,000 simulations of the patient's entire lifetime post‐treatment were performed and compared to the patient's clinically‐documented outcomes (wherever available).
Results
94.4% of simulations exhibited locoregional control, compared to 89.9% of patients in clinical reality. Simulated death with locoregional failure was 4.9%, compared to 5.4% in real life. Patients developed and died with distant metastases in 8.0% of simulations, while 10.8% of patients developed distant metastases in real life and 5.7% of patients passed away with distant disease. The simulated second primary cancer rate was 13.5%. Patients exhibited at least one healthy tissue toxicity in 43.8% of simulations, and simulated life expectancy and QALE were 76.5 ± 11.6 years and 74.3 ± 11.0 quality‐adjusted life years (QALYs), respectively.
Conclusions
Agreement between simulation results and available clinically‐documented outcomes was generally excellent, enabling the evaluation of prospective clinical outcomes and comparisons between different patient populations along with variable treatment combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INSA-Lyon, Universite Claude Bernard Lyon 1, CNRS, Inserm, CREATIS UMR 5220, U1294, Lyon, France.
- Life Sciences Division, Vancouver, British Columbia, Canada.
- Department of Radiation Oncology, Centre Léon Bérard, Lyon, France.
- Department of Radiation Oncology, Beaumont University Hospital - Corewell Health, Royal Oak, Michigan, USA.
Förderung
- ANR HERESP
- LabEx PRIMES
- SIRIC LyriCAN+
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Tattenberg, S., Allignet, B., Ding, X., Hoehr, C., Chen, P., & Beuf, O. (2026). Expansion and clinical validation of Markov model‐based quality‐adjusted life expectancy (QALE) simulations for head‐and‐neck cancer radiotherapy patients. Medical Physics. https://doi.org/10.1002/mp.70696
Vancouver
Tattenberg S, Allignet B, Ding X, Hoehr C, Chen P, Beuf O. Expansion and clinical validation of Markov model‐based quality‐adjusted life expectancy (QALE) simulations for head‐and‐neck cancer radiotherapy patients. Medical Physics. 2026. doi:10.1002/mp.70696
BibTeX
@article{Tattenberg2026,
author = {Tattenberg, Sebastian and Allignet, Benoit and Ding, Xuanfeng and Hoehr, Cornelia and Chen, Peter and Beuf, Olivier},
title = {Expansion and clinical validation of Markov model‐based quality‐adjusted life expectancy (QALE) simulations for head‐and‐neck cancer radiotherapy patients},
journal = {Medical Physics},
year = {2026},
doi = {10.1002/mp.70696}
}
EUVIMED